Small-molecule oral GLP-1 RAs, such as orforglipron and danuglipron, are in development or early clinical trials
The body's glucose-sensing mechanisms, which have adapted to chronically elevated blood sugar levels, may initially interpret normal or improved glucose levels as relatively low, potentially triggering hunger signals and cravings for quick-acting carbohydrates
Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease
For many people, adopting a calorie deficit alongside increased physical activity will produce gradual, safe reductions in visceral fat without the need for medical intervention
"Any future switch would come down to how well your current treatment is working for you, how well you tolerate it, and whether a different format genuinely makes it easier to stay on track long term, rather than preference alone. Aniyah Mansuri , weight loss expert at myBMI Sources Once-weekly semaglutide 72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial (2025)